NaF-PET drives management of prostate cancer, registry data suggest

03/19/2014 | (free registration)

Data from the National Oncologic PET Registry revealed that NaF-PET led to a change in treatment strategy in 77% of patients staged using the approach. Management was also changed in 52% of patients believed to have initial bone metastases and 71% of patients whose bone metastases are believed to be progressing. "These data reflect referring physicians' confidence (or overconfidence) in NaF-PET's value in stratifying risk and their willingness to make definitive plans immediately," the authors wrote in the Journal of Nuclear Medicine.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC